RE: Stifel and Jefferies analystsChristine Charette, once the best analyst in the canadian biotech sector gave a target of between $17 and $28 on TH shortly before leaving BMO research group.
Unfortunately, analysts value to the eyes of their firm sometimes obey more to the law of greed than the validity of their research.
My take on Thera's management decision to increase 20% the number of shares?
NOT GOOD.
Why are they doing this if their product is so close to be on the market?
Why not borrow $30M @ 9% from La Caisse for 5 years?
If you are to have steady Cash Flows of $100M/year starting 2012 couldn't it be less costly?
Theratechnologies has a history full of surprises. This one will not be the last one.
I guess once again, shareholders will have to be patient. I am one of them...